Navigation Links
OncoGenex Pharmaceuticals Added to Russell Indexes
Date:6/30/2009

BOTHELL, WA, and VANCOUVER, June 30 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), a biopharmaceutical company committed to the development and commercialization of new therapies that address unmet needs in the treatment of cancer, announced today that the Company was added to the Russell 3000(R) Index, the Russell 2000(R) Index and the Russell Microcap(R) Index at the close of market on June 26, 2009 as part of the annual reconstitution of Russell indexes.

The Russell 3000 Index measures the performance of the largest 3000 U.S. companies representing approximately 98% of the investable U.S. equity market. The Russell 3000 Index is constructed to provide a comprehensive, unbiased, and stable barometer of the broad market and is completely reconstituted annually to ensure new and growing equities are reflected.

The Russell 2000 Index measures the performance of the small-cap segment of the U.S. equity universe. The Russell 2000 Index is a subset of the Russell 3000 Index representing approximately 10% of the total market capitalization of that index. The Russell 2000 is constructed to provide a comprehensive and unbiased small-cap barometer.

The Russell Microcap Index measures the performance of the microcap segment of the U.S. equity market. It makes up less than 3% of the U.S. equity market. It includes 1000 of the smallest securities in the small-cap Russell 2000(R) Index. Russell Microcap Index is constructed to provide a comprehensive and unbiased barometer for the microcap segment trading on national exchanges, while excluding lesser-regulated OTC bulletin board securities and pink-sheet stocks due to their failure to meet national exchange listing requirements.

The Russell 2000 and Microcap Indexes are reconstituted annually to ensure larger stocks do not distort performance and characteristics of the
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. OncoGenex Pharmaceuticals Files Shelf Registration Statement
2. OncoGenex Pharmaceuticals Completes Amendment to Phase 3 Special Protocol Assessment for Confirming Survival Benefit in Patients Receiving OGX-011 with First-Line Docetaxel for Metastatic Prostate Cancer
3. OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer
4. OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
5. OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009
6. OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427
7. OncoGenex Pharmaceuticals Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting
8. OncoGenex Reports First Quarter Financial Results
9. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
10. OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer
11. OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... --  SunTrust Robinson Humphrey (STRH) today announced ... equity research team in biotechnology and oilfield services.  ... research demonstrates our commitment to providing our valued ... investment decision making," said Biff Woodruff , ... make significant investments in differentiated content at a ...
(Date:8/28/2014)... 28, 2014 A new market ... world is available from Strategic Consulting, Inc., the ... Industrial Microbiology Market Review, Fourth Edition: Global Review ... (IMMR—4) tracks and compares microbiology test volumes, market ... Europe and Asia, and forecasts future volumes and ...
(Date:8/27/2014)... Salt Lake City, Utah (PRWEB) August 27, 2014 ... new construction that will expand its current Salt Lake ... operations currently underway outside of Utah to ultimately create ... the next 20 years. , “Utah is home ... many of whom can be credited with Varian’s success ...
(Date:8/27/2014)... 2014   MSC , a healthcare performance improvement ... the appointment of Mary Beth Loesch to ... of experience preparing companies for rapid growth and market ... President of Corporate Development and Healthcare. In that role, ... as well as corporate strategy and marketing. Previously, Loesch ...
Breaking Biology Technology:SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 2SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 32 Billion Industrial Microbiology Tests Conducted for Product Quality and Safety Worldwide 22 Billion Industrial Microbiology Tests Conducted for Product Quality and Safety Worldwide 3Varian Medical Systems Groundbreaking on Facility Expansion Triggers Influx of New Jobs to Salt Lake 2Varian Medical Systems Groundbreaking on Facility Expansion Triggers Influx of New Jobs to Salt Lake 3MSC names Mary Beth Loesch President and CEO 2
... Today, Jazz,Pharmaceuticals, Inc. (Nasdaq: JAZZ ) announced ... issued an approvable letter for Once-A-Day,LUVOX(R) CR (fluvoxamine ... Pharmaceuticals, Inc. are seeking marketing,approval for the treatment ... obsessive compulsive disorder (OCD)., The FDA requested ...
... Protein Exports, and Biofuels Key Issues in 2008, ... country,of origin labeling and developments in biofuels are some ... & Agribusiness Outlook., The Outlook is produced annually ... provides information and analysis covering all of,the major sectors ...
... SOUTH SAN FRANCISCO, Calif., Dec. 21 Anesiva,Inc. ... of its public offering,of 11,111,111 shares of its ... their option to purchase an additional 1,234,568 shares.,The ... from the sale of the aggregate 12,345,679 shares ...
Cached Biology Technology:FDA Issues Approvable Letter for LUVOX(R) CR (Fluvoxamine Maleate) Extended-Release Capsules for the Treatment of Social Anxiety Disorder (SAD) and Obsessive Compulsive Disorder (OCD) 2Rabobank Releases Annual North American Food & Agribusiness Outlook 2Rabobank Releases Annual North American Food & Agribusiness Outlook 3Rabobank Releases Annual North American Food & Agribusiness Outlook 4
(Date:8/28/2014)... the most commonly diagnosed learning disability in the ... occurs when the regions of the brain that ... use of non-invasive functional neuroimaging tools has helped ... However, most prior work has focused on only ... gap in our understanding of how multiple brain ...
(Date:8/28/2014)... mould in homes could pose a significant health risk to ... the Journal of Allergy and Clinical Immunology . , ... different countries, the research has found that the presence of ... asthma sufferers, as well as increasing the likelihood of developing ... team at the University of Exeter Medical School and is ...
(Date:8/28/2014)... more action is needed to ensure safeguards are in ... in PLOS ONE , researchers from Monash University, ... - combining results from different studies - to look ... areas, to determine whether they actually protect biodiversity. ... protecting an area from human exploitation made common sense, ...
Breaking Biology News(10 mins):Dyslexic readers have disrupted network connections in the brain 2Indoor mold poses health risk to asthma sufferers 2Protected areas proven to protect biodiversity 2
... innovative systems biology approach to understanding the carbohydrate structures ... how inflammatory illnesses and cardiovascular disease develop in humans. ... University at Buffalo chemical engineers. , Supported by ... ultimate goal of the project is to define novel ...
... Eastman Dental Center,s Hyun (Michel) Koo, D.D.S, Ph.D., $1.6 ... the single most prevalent and costly oral infectious disease ... results from the interaction of specific bacteria (such as ... using sucrose to help them, and other pathogens, to ...
... N.J. Dr. Dilhan Kalyon, Professor of Chemical ... Institute at Stevens Institute of Technology, has won ... The award, sponsored by Shell Global Solutions, Inc., ... made a significant impact in the field of ...
Cached Biology News:Researchers apply systems biology and glycomics to study human inflammatory diseases 2Researchers apply systems biology and glycomics to study human inflammatory diseases 3Eastman Dental Center awarded $1.6 million to find ways to prevent cavities 2